| NANOX-HEALTH-IT-INC |
NANOX-HEALTH-IT-INC |
85%
|
d revenue. Our subsidiary, Nanox Health IT Inc. (formerly: Vaso Healthcare IT Corp.) (“Nanox Health IT”), a healthcare information technology provider serving hospitals and healthcare providers acros… |
| NANO-X-IMAGING-INC |
NANO-X-IMAGING-INC |
85%
|
e “Vaso SPA”), among Nano-X Imaging Inc., the Company’s wholly owned subsidiary (“Nanox Inc.”), Vaso IT, and Vaso Corporation, a Delaware Corporation, the parent company of Vaso IT (“Vaso Corp”). Pur… |
| USARAD-HOLDINGS-INC |
USARAD-HOLDINGS-INC |
85%
|
. Following our acquisition of USARAD in November 2021, we offer teleradiology services to customers in the U.S. market and an additional six countries by U.S.-based radiologists, certified by the Am… |
| VASO-HEALTHCARE-IT-CORP |
VASO-HEALTHCARE-IT-CORP |
85%
|
d revenue. Our subsidiary, Nanox Health IT Inc. (formerly: Vaso Healthcare IT Corp.) (“Nanox Health IT”), a healthcare information technology provider serving hospitals and healthcare providers acros… |
| VASO-SPA-VASO-CORP |
VASO-SPA-VASO-CORP |
85%
|
e “Vaso SPA”), among Nano-X Imaging Inc., the Company’s wholly owned subsidiary (“Nanox Inc.”), Vaso IT, and Vaso Corporation, a Delaware Corporation, the parent company of Vaso IT (“Vaso Corp”). Pur… |
| FN |
Fabrinet |
72%
|
Reciprocal relationship from FN graph: Reciprocal relationship from NNOX graph: Reciprocal relationship from FN graph: Reciprocal relationship from NNOX graph: Reciprocal relationship from FN graph: … |
| FN |
Fabrinet |
72%
|
Varex will supply X-ray tubes utilizing the Nanox digital X-ray emitter for the Nanox.ARC system. The agreement was entered into after Varex completed a preliminary assessment of our digital X-ray em… |
| VREX |
Varex Imaging Corporation |
72%
|
jurisdictions, based on, among other things, cost effectiveness. We are currently developing both ceramic and glass-based digital X-ray tubes for use in the Nanox.ARC and the Nanox.ARC X. We are work… |
| VREX |
Varex Imaging Corporation |
72%
|
Reciprocal relationship from VREX graph: Reciprocal relationship from NNOX graph: jurisdictions, based on, among other things, cost effectiveness. We are currently developing both ceramic and glass-b… |
| COMPANY-NANOX-IMAGING-PLC |
COMPANY-NANOX-IMAGING-PLC |
62%
|
ive values of currencies occur regularly and, in some instances, may have a significant impact on our operating results. The rate of inflation in Israel or Korea or in currency exchange rates may mat… |
| CT-CORPORATION |
CT-CORPORATION |
62%
|
nel specializing in healthcare IT implementation. Nanox Health IT provides services exclusively to healthcare organizations, including imaging centers, radiology groups, hospitals and healthcare netw… |
| DAGESH-P-K-LTD |
DAGESH-P-K-LTD |
62%
|
or any termination of or dispute under these arrangements, could materially delay our commercialization timelines, reduce our revenue, and adversely affect our business, financial condition, and resu… |
| FET-JAPAN-INC |
FET-JAPAN-INC |
62%
|
. Following our acquisition of USARAD in November 2021, we offer teleradiology services to customers in the U.S. market and an additional six countries by U.S.-based radiologists, certified by the Am… |
| FIELD-EMISSION-TECHNOLOGIES-INC |
FIELD-EMISSION-TECHNOLOGIES-INC |
62%
|
. Following our acquisition of USARAD in November 2021, we offer teleradiology services to customers in the U.S. market and an additional six countries by U.S.-based radiologists, certified by the Am… |
| IT-CORP |
IT-CORP |
62%
|
lthcare IT Corp.) (“Nanox Health IT”), a healthcare information technology provider serving hospitals and healthcare providers across the United States, resells and supports third-party healthcare IT… |
| MDWEB-LLC |
MDWEB-LLC |
62%
|
or any termination of or dispute under these arrangements, could materially delay our commercialization timelines, reduce our revenue, and adversely affect our business, financial condition, and resu… |
| MEDICAL-DEVICE-COORDINATION-GROUP |
MEDICAL-DEVICE-COORDINATION-GROUP |
62%
|
harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of these laws, includi… |
| MIZUHO-SECURITIES-USA-LLC |
MIZUHO-SECURITIES-USA-LLC |
62%
|
nel specializing in healthcare IT implementation. Nanox Health IT provides services exclusively to healthcare organizations, including imaging centers, radiology groups, hospitals and healthcare netw… |
| NANO-X-AI-LTD |
NANO-X-AI-LTD |
62%
|
or any termination of or dispute under these arrangements, could materially delay our commercialization timelines, reduce our revenue, and adversely affect our business, financial condition, and resu… |
| NANOX-GIBRALTAR-PLC |
NANOX-GIBRALTAR-PLC |
62%
|
consumers. Following the Californian example, various U.S. states have passed, or are in the process of passing, similar state privacy laws. Non-compliance with state privacy laws could result in reg… |
| NANOX-IMPACT-INC |
NANOX-IMPACT-INC |
62%
|
eholders an additional 2,648,424 ordinary shares. As a result of the settlement, both parties’ performance obligations under the agreement have been satisfied in full. On January 1, 2024, we incorpor… |
| RADIOLOGY-PARTNERS |
RADIOLOGY-PARTNERS |
62%
|
ned from customers, partners and third parties, often under agreements that restrict scope, duration, de-identification methods, permitted uses and model training. Evolving privacy laws, guidance on … |
| RE-MEDI-CO-LTD |
RE-MEDI-CO-LTD |
62%
|
ation, and after-sales support. Additionally, they will execute marketing activities, maintain inventory, manage financial transactions with Nanox, and set local pricing and negotiate with customers.… |
| USARAD-HOLDINGS |
USARAD-HOLDINGS |
62%
|
nel specializing in healthcare IT implementation. Nanox Health IT provides services exclusively to healthcare organizations, including imaging centers, radiology groups, hospitals and healthcare netw… |
| ZEBRA-MEDICAL-VISION-LTD |
ZEBRA-MEDICAL-VISION-LTD |
62%
|
or any termination of or dispute under these arrangements, could materially delay our commercialization timelines, reduce our revenue, and adversely affect our business, financial condition, and resu… |
